No Data
No Data
Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) 129% Share Price Surge Not Quite Adding Up
Changjiang Pharmaceutical Group (300391.SZ): Elects Wang Bo as the company's director.
On July 1st, Gelunhui reported that Changjiang Pharmaceutical Group (300391.SZ) held the 17th meeting of the fifth board of directors on July 1, 2024, and approved the Proposal on the Election of the Chairman of the Fifth Board of Directors and the Proposal on the Appointment of the General Manager. The board of directors elected Wang Bo as the chairman of the fifth board of directors of the company, with a term of office consistent with that of the fifth board of directors. The board of directors appointed Hu Shihui as the general manager of the company, with a term of office from the date of appointment to the end of this term of the board of directors. This matter has been approved by the Nomination Committee of the Board of Directors of the Company at its second meeting in 2024.
Analysis of BT Financial Report: Changjiang Pharmaceutical Group's Q1 2024 report shows both declining performance and financial pressure.
Changjiang Pharmaceutical Group Co., Ltd. (stock code: 300391), also known as ChangYaoKongGu, is a company focused on pharmaceutical research and development, production, and sales. The company is committed to providing high-quality pharmaceutical products and services to meet market demand. However, the financial report data for the first quarter of 2024 showed that the company is facing severe financial challenges. At the end of this reporting period, the total assets of Changjiang Pharmaceutical Group were 3.432 billion yuan, a decrease of 0.4% from the end of the previous year's 3.446 billion yuan. The asset-liability ratio increased from the beginning of the period of 70.48% to the end of the period of 72.72%, indicating the pressure the company is facing in terms of debt.
Changjiang Pharmaceutical Group (300391.SZ): Received a letter from the independent director urging action.
Changjiang Pharmaceutical Group (300391.SZ) announced that they have received a supervision letter jointly submitted by independent directors Mr. Deng Yuanjun, Ms. Lan Xia, and Mr. Wu Kangbing regarding the promotion of self-examination and correction and relevant work of Changjiang Pharmaceutical.
Changyao Holdings (300391.SZ) announced first-quarter results with a net loss of 47.5059 million yuan, an increase of 106.92%
According to the Zhitong Finance App, Changyao Holdings (300391.SZ) released its report for the first quarter of 2024. The company's revenue was 59.9018 million yuan, a year-on-year decrease of 56.80%. The net loss attributable to shareholders of listed companies was 47.5059 million yuan, an increase of 106.92% over the previous year. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 456.596 million, an increase of 97.65% over the previous year. The basic loss per share was $0.1356.
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Surges 52% Yet Its Low P/S Is No Reason For Excitement
No Data